Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Items 101–200 of 848
Vito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 119
Lee, D. J., Lee, H. J., Farmer, J. R., & Reynolds, K. L. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01530-2 · Cited by 108
Deshpande, R. P., Sharma, S., & Watabe, K. (2020) · Cancers · doi:10.3390/cancers12102983 · Cited by 107
“Another study demonstrated that interaction between tumor PD-L1 with PD-1 expressed by NK cells inhibits the antitumor responses of NK cells, leading to aggressive tumor growth [21].”
BackgroundYin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 120
CAR-NK cell therapy: promise and challenges in solid tumors
Balkhi, S., Zuccolotto, G., Spirito, A. D., Rosato, A., & Mortara, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1574742 · Cited by 109
“Disrupting these signaling pathways has been shown to enhance NK cell anti-cancer activity (176, 177).”
Harnessing NK Cells for Cancer Treatment
Minetto, P., Guolo, F., Pesce, S., Greppi, M., Obino, V., Ferretti, E., Sivori, S., Genova, C., Lemoli, R., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02836 · Cited by 81
“Recent data strongly suggest a possible role for NK cells in immunotherapeutic strategies targeting the PD-1/PD-L1 axis particularly against HLA-I-deficient tumor cells (40, 41).”
BackgroundXia, Q., Jia, J., Hu, C., Lu, J., Li, J., Xu, H., Fang, J., Feng, D., Wang, L., & Chen, Y. (2021) · Oncogene · doi:10.1038/s41388-021-02133-5 · Cited by 105
“PKM2-mediated enhancement of PD-L1 expression in PDAC is inversely related to antitumor immunity of NK cells Studies have shown that PD-L1-transduced tumor cells suppress immune resistance and that the removal of NK cells abrogates antitumor efficacy of PD-1 blockade, indicating that NK cells are responders to checkpo…”
BackgroundExosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
Yu, Y. (2023) · Cancers · doi:10.3390/cancers15082323 · Cited by 107
“These indicate that inhibiting PD-1/PD-L1 signaling could significantly promote the capability of NK cells to antitumor progression, implicating that combined therapy with PD-1/PD-L1 on NK cells is a reasonable approach for NK cell-based therapy [260].”
BackgroundCytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
Ghasemi, A., Martínez-Usatorre, A., Li, L., Hicham, M., Guichard, A., Marcone, R., Fournier, N., Torchia, B., Bedoya, D. M., Davanture, S., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00668-y · Cited by 102
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Río, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 101
Dynamic Natural Killer Cell and T Cell Responses to Influenza Infection
Frank, K., & Paust, S. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00425 · Cited by 103
“NK cells are increasingly credited as important contributors to the improved outcomes of patients receiving checkpoint blockade therapies targeting these immunosuppressive mechanisms (Wiesmayr et al., 2012; Beldi-Ferchiou et al., 2016; Hsu et al., 2018).”
BackgroundThe immune landscape of common CNS malignancies: implications for immunotherapy
Ott, M., Prins, R. M., & Heimberger, A. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00518-9 · Cited by 106
Boosting Checkpoint Immunotherapy with Biomaterials
Liu, L., Pan, Y., Zhao, C., Huang, P., Chen, X. S., & Rao, L. (2023) · ACS Nano · doi:10.1021/acsnano.2c11691 · Cited by 100
Zhao, Z., Ukidve, A., Krishnan, V., Fehnel, A., Pan, D. C., Gao, Y., Kim, J., Evans, M. A., Mandal, A., Guo, J., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00644-2 · Cited by 101
Naik, A., Monjazeb, A. M., & Decock, J. V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01940 · Cited by 100
Zhu, G., Pei, L., Li, Y., & Gou, X. (2020) · Aging · doi:10.18632/aging.102728 · Cited by 100
“which supported the previous findings that such immune cells and pathways play predominant roles in the tumor microenvironment and promote the immune response [18, 19].”
ResultThe role of natural killer cell in gastrointestinal cancer: killer or helper
Wang, F., Lau, J. K. C., & Yu, J. Q. (2020) · Oncogene · doi:10.1038/s41388-020-01561-z · Cited by 97
Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
Chen, X., Xu, Z., Li, T., Thakur, A., Wen, Y., Zhang, K., Liu, Y., Liang, Q., Liu, W., Qin, J., et al. (2024) · Biomarker Research · doi:10.1186/s40364-023-00551-z · Cited by 96
“Recent studies have revealed that PD-1/PD-L1 interactions inhibit NK cell responses [119].”
ResultXiao, L., Zhang, L., Guo, C., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2024) · 癌症:英文版 · doi:10.1002/cac2.12579 · Cited by 95
“The expression of PD-1 inhibits the function of various immune cells in the TME, including T cells [360], B cells [361], NK cells [362], and DCs [363].”
BackgroundSelf-citationTrefny, M. P., Kaiser, M., Stanczak, M. A., Herzig, P., Savic, S., Wiese, M. N., Lardinois, D., Laubli, H. P., Uhlenbrock, F., & Zippelius, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02558-z · Cited by 89
NK cells-directed therapies target circulating tumor cells and metastasis
Dianat‐Moghadam, H., Mahari, A., Heidarifard, M., Parnianfard, N., Pourmousavi-Kh, L., Rahbarghazi, R., & Amoozgar, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.021 · Cited by 90
NK cell-based tumor immunotherapy
Zhang, H., Yang, L., Wang, T., & Li, Z. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.001 · Cited by 99
“Several tumor mouse models showed that PD-1/PD-L1 interactions potently suppress NK cell-mediated immunotherapy [102].”
BackgroundTargeting tumor-associated macrophages in head and neck squamous cell carcinoma
Li, B., Ren, M., Zhou, X., Han, Q., & Cheng, L. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104723 · Cited by 90
Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways
Taghiloo, S., & Asgarian‐Omran, H. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103164 · Cited by 93
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Tumino, N., Pace, A. L. D., Besi, F., Quatrini, L., Vacca, P., & Moretta, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.638841 · Cited by 90
NK and NKT cells have distinct properties and functions in cancer
Liu, X., Li, L., Si, F., Huang, L., Zhao, Y., Zhang, C., Hoft, D. F., & Peng, G. (2021) · Oncogene · doi:10.1038/s41388-021-01880-9 · Cited by 97
Fitzgerald, A. A., Wang, S., Agarwal, V. R., Davis-Marcisak, E. F., Zuo, A., Jablonski, S. A., Loth, M., Fertig, E. J., MacDougall, J. R., Zhukovsky, E. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002837 · Cited by 87
Zhan, M., Qiu, J., Fan, Y., Chen, L., Guo, Y., Wang, Z., Li, J., Majoral, J., & Shi, X. (2022) · Advanced Materials · doi:10.1002/adma.202208277 · Cited by 83
Lifting the innate immune barriers to antitumor immunity
Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 88
Circulating CD56bright NK cells inversely correlate with survival of melanoma patients
de Jonge, K., Ebering, A., Nassiri, S., Hajjami, H. M.-E., Ouertatani-Sakouhi, H., Baumgaertner, P., & Speiser, D. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-40933-8 · Cited by 82
Ji, T., Lang, J., Ning, B., Qi, F., Wang, H., Zhang, Y., Zhao, R., Yang, X. P., Zhang, L., Li, W., et al. (2018) · Advanced Materials · doi:10.1002/adma.201804395 · Cited by 81
Self-citationα-Pinene Enhances the Anticancer Activity of Natural Killer Cells via ERK/AKT Pathway
Jo, H., Cha, B., Kim, H., Brito, S., Kwak, B.-M., Kim, S. T., Bin, B., & Lee, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020656 · Cited by 81
“A third example is the targeting of the inhibitory receptors of NK cells, such as PD1/PD-L1 blockade [18,19], mAbs to KIRs [20,21], mAbs to NKG2A [22], TIGIT/CD96 blockade [23] and TIM-3 blockade [24,25].”
BackgroundDu, F., Qi, X., Zhang, A., Sui, F., Wang, X., Proud, C. G., Lin, C., Fan, X., & Li, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00670-3 · Cited by 86
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer
Nersesian, S., Glazebrook, H. M., Toulany, J., Grantham, S. R., & Boudreau, J. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01782 · Cited by 90
“A recent study investigated the therapeutic effect of anti-PD1 therapy on NK cells using several mouse cancer models and concluded that NK cells were crucial to anti-tumor responses (114).”
BackgroundOhmura, H., Yamaguchi, T., Hanamura, F., Ito, M., Makiyama, A., Uchino, K., Shimokawa, H., Tamura, S., Esaki, T., Mitsugi, K., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0810-1 · Cited by 80
Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors
Oh, S., Lee, J., Kwack, K., & Choi, S.-W. (2019) · Cancers · doi:10.3390/cancers11101534 · Cited by 71
“In mouse models of cancer, NK cells expressed PD-1 and cancer cells expressed PD-L1, and a PD-1/PD-L1 blockade elicited a strong NK cell response [109].”
BackgroundSelective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance
Hofmann, M. H., Mani, R., Engelhardt, H., Impagnatiello, M. A., Carotta, S., Kerenyi, M. A., Lorenzo‐Herrero, S., Böttcher, J., Scharn, D., Arnhof, H., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0789 · Cited by 84
“Protein production and structural analysis CDK8 (1-403) containing an N-terminal His6-tag followed by a TEV cleavage site was coexpressed with cyclin C (CycC, 1-283) containing an N-terminal GST-tag and a TEV cleavage site in Trichoplusia ni cells (BaculoDirect, Thermo Fisher).”
BackgroundMethodInnate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma
Wang, Z., Wang, Z., Li, B., Wang, S., Chen, T., & Ye, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01114 · Cited by 76
“Importantly, a recent clinical study demonstrated that blocking PD-1 and PDL1 elicited a strong NK cell response that was indispensable for the full therapeutic effects of immunotherapy (139).”
BackgroundTherapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 82
“…anti-PD-L1 antibodies results in enhanced anti-tumour efficacy by, respectively, depleting Tregs and destroying cancer cells [111,112,114], the opposite effect is observed with anti-Pd-1 antibodies where the elimination of Pd-1 + T cells and NK cells diminishes its anti-tumour efficacy [114,115].”
Liu, G., Zhang, Q., Yang, J., Li, X., Xian, L., Li, W., Lin, T., Cheng, J., Lin, Q., Xu, X., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02978-5 · Cited by 80
“It has been reported that PD-L1/PD-1 axis involved in inhibition of NK function, and blockade of this axis elicited a strong NK response in vivo in certain types of mouse tumor models [33].”
Liu, Y., Xu, Q., Deng, F., Zheng, Z., Luo, J., Wang, P., Zhou, J., Lu, X., Zhang, L., Chen, Z., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02609-0 · Cited by 83
“Both PD-1 and PD-L1 blockade elicited a potent NK cell response as well [41].”
Self-citationGoldenson, B., Zhu, H., Wang, Y., Heragu, N., Bernareggi, D., Ruiz-Cisneros, A., Bahena, A., Ask, E. H., Hoel, H. J., Malmberg, K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.561553 · Cited by 67
Wang, Q., Wang, J., Yu, D., Zhang, Q., Hu, H., Xu, M., Zhang, H., Tian, S., Zheng, G., Lu, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101357 · Cited by 97
Mariotti, F., Quatrini, L., Munari, E., Vacca, P., & Moretta, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00910 · Cited by 71
“The contribution of PD-1 blockade on NK cells in immunotherapy has been demonstrated in several mouse models of cancer, where PD-1 engagement by PD-L1 tumor cells could strongly suppress NK cell–mediated anti-tumor immunity (79).”
BackgroundInhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
Buckle, I., & Guillerey, C. (2021) · Cancers · doi:10.3390/cancers13174263 · Cited by 79
“While naïve mouse NK cells do not express PD-1 [79–81], a fraction of PD-1+ tumorinfiltrating NK cells has been observed in various mouse subcutaneous and spontaneous genetically induced mouse cancer models [79].”
BackgroundInfluentialYu, L., Huang, K., Liao, Y., Wang, L., Sethi, G., & Ma, Z. (2024) · Cell Proliferation · doi:10.1111/cpr.13644 · Cited by 79
Diversity of immune checkpoints in cancer immunotherapy
Guo, Z., Zhang, R., Yang, A., & Zheng, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121285 · Cited by 82
Holzgruber, J., Martins, C. P., Kulcsár, Z., Duplaine, A., Rasbach, E., Migayron, L., Singh, P. K., Statham, E., Landsberg, J., Boniface, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51496-2 · Cited by 77
“Thermal cycling was carried out as described 35,36,57 at annealing temperatures shown in Supplementary Tables 1 – 4, followed by subsequent melt-curve validation.”
Jewett, A., Kos, J., Kaur, K., Safaei, T., Sutanto, C., Chen, W., Wong, P., Namagerdi, A. K., Fang, C., Fong, Y., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.11.002 · Cited by 75
Metabolism of Natural Killer Cells and Other Innate Lymphoid Cells
Cong, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01989 · Cited by 81
“Immune Checkpoints Emerging immune checkpoint blockade strategies are being tested for their potential to reverse NK cell dysfunction in cancer and chronic viral infections, and there is evidence that anti-PD-1 or anti-PD-L1 antibody can enhance the anti-tumor efficacy of NK cells in multiple tumor models (138, 139).”
BackgroundLanuza, P. M., Pesini, C., Arias, M. A., Calvo, C., Ramírez-Labrada, A., & Pardo, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03010 · Cited by 75
Advances in NK cell therapy for brain tumors
Fares, J., Davis, Z., Rechberger, J. S., Toll, S. A., Schwartz, J., Daniels, D. J., Miller, J. S., & Khatua, S. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00356-1 · Cited by 76
Davies, D., Kamdar, S., Woolf, R., Zlatareva, I., Iannitto, M. L., Morton, C., Haque, Y., Martin, H., Biswas, D., Ndagire, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00690-0 · Cited by 75
“However, this does not diminish the importance of αβ T cells, nor that of other immune cells expressing PD-1 (for example, NK cells, macrophages) 70,71 , which most likely act in concert to seal off multiple paths of the immune evasion arising during tumor evolution.”
BackgroundPhase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Patel, S. P., Alonso‐Gordoa, T., Banerjee, S. N., Wang, D., Naidoo, J., Standifer, N. E., Palmer, D. C., Cheng, L., Kourtesis, P., Ascierto, M. L., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007340 · Cited by 73
Building a Better Defense: Expanding and Improving Natural Killer Cells for Adoptive Cell Therapy
Maia, A., Tarannum, M., Lérias, J. R., Piccinelli, S., Borrego, L. M., Maeurer, M. J., Romee, R., & Castillo-Martín, M. (2024) · Cells · doi:10.3390/cells13050451 · Cited by 74
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Haines, B. B., Denslow, A., Grzesik, P., Lee, J. S., Farkaly, T., Hewett, J., Wambua, D., Kong, L., Behera, P., Jacques, J., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0609 · Cited by 73
“These results showed that mONCR-171 could elicit durable antitumor responses and tumor antigen–specific protective memory responses. mONCR-171 administration recruitments antitumor immune cells to the TME Intratumoral administration of mONCR-171 resulted in a significant increase in the median T-cell density for injec…”
InfluentialUnraveling exhaustion in adaptive and conventional NK cells
Merino, A. M., Kim, H., Miller, J. S., & Cichocki, F. M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0620-091r · Cited by 69
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
Shaver, K. A., Croom-Perez, T. J., & Copik, A. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679117 · Cited by 74
“2) PD-1 expression in NK cells has been shown to be upregulated in a variety of cancers (26, 60, 61) and to be”
BackgroundInfluentialYoun, J., Park, S.-M., Park, S., Kim, G., Lee, H., Son, J., Hong, M. H., Ghaderpour, A., Baik, B., Islam, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-65666-x · Cited by 68
Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer
Bödder, J., Zahan, T., van Slooten, R., Schreibelt, G., de Vries, I. J. M., & Flórez‐Grau, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.631713 · Cited by 72
“Especially in low MHC-I expressing tumors, the effect of mAbs blocking PD-1/PDL-1 might partly be facilitated by NK cells (136).”
BackgroundBispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Kotanides, H., Li, Y., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I., Surguladze, D., Pennello, A. L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0304 · Cited by 65
“NK cells can mediate antitumor response to PD-1 pathway inhibitors (41).”
BackgroundDeng, R., Zuo, C., Li, Y., Xue, B., Xun, Z., Guo, Y., Wang, X., Xu, Y., Tian, R., Chen, S., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00549-9 · Cited by 72
Chung, Y. M., Khan, P. P., Wang, H., Tsai, W.-B., Qiao, Y., Yu, B., Larrick, J. W., & Hu, M. C. ‐. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002772 · Cited by 69
Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors
Lian, G., Mak, T. S., Yu, X., & Lan, H. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010164 · Cited by 72
The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
Michie, J., Kearney, C. J., Hawkins, E. D., Silke, J., & Oliaro, J. (2020) · Cells · doi:10.3390/cells9010207 · Cited by 73
Mechanisms of Resistance to NK Cell Immunotherapy
Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 70
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
“However, no such effect occurring with depletion of CD4+ and CD8+ T cells indicates that NKs take a vital position in immune checkpoint blockade (Hsu et al., 2018).”
BackgroundDai, S., Chen, Y., Cai, W., Dong, S., Zhao, J., Chen, L., & Cheng, C. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01739-6 · Cited by 73
“Natural killer (NK) cells expressing PD-1, especially activated subsets marked by Sca-1 ⁺ and CD69 ⁺ , exhibit enhanced cytotoxicity following PD-1 blockade, further amplifying the antitumor immune treatment response [95].”
Landscape of natural killer cell activity in head and neck squamous cell carcinoma
Charap, A., Enokida, T., Brody, R., Sfakianos, J. P., Miles, B. A., Bhardwaj, N., & Horowitz, A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001523 · Cited by 81
CD28 Homolog Is a Strong Activator of Natural Killer Cells for Lysis of B7H7+ Tumor Cells
Zhuang, X., & Long, E. O. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0733 · Cited by 68
“However, expression of checkpoint coinhibitory receptors, such as PD-1 and LAG-3, is usually induced or upregulated onNK cells after activation (37, 38).”
BackgroundBi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy
Phung, S. K., Miller, J. S., & Felices, M. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00550-6 · Cited by 64
Cai, S., Chen, Z., Wang, Y., Wang, M., Wu, J., Tong, Y., Chen, L., Lü, C., & Yang, H. (2020) · Theranostics · doi:10.7150/thno.45777 · Cited by 65
“It should be noted that PD-1 and PD-L1 blockade elicited CD8+ CTL and NK cell response [37,38].”
BackgroundMikelez-Alonso, I., Magadán, S., González‐Fernández, Á., & Borrego, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113860 · Cited by 64
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK
Giles, A. J., Hao, S., Padget, M. R., Song, H., Zhang, W., Lynes, J. P., Sánchez, V., Liu, Y., Jung, J., Cao, X., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130688 · Cited by 63
Huang, F., Gonçalves, C., Bartish, M., Rémy-Sarrazin, J., Issa, M. E., Cordeiro, B., Guo, Q., Émond, A., Attias, M., Yang, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140752 · Cited by 69
“Similarly, in the aggressive triple-WT B16-pdl1 melanoma model (75), we showed that combined MNK1/2 inhibition and anti–PD-1 resulted in augmented tumor control and significantly improved overall survival (Figure 9, A and B).”
BackgroundCamelliti, S., Noci, V. L., Bianchi, F., Moscheni, C., Arnaboldi, F., Gagliano, N., Balsari, A., Garassino, M. C., Tagliabue, E., Sfondrini, L., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01721-9 · Cited by 67
Raková, J., Truxová, I., Holíček, P., Šálek, C., Hensler, M., Kašíková, L., Pasulka, J., Holubová, M., Kovář, M., Lysák, D., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1889822 · Cited by 67
Russick, J., Torset, C., Hemery, E., & Cremer, I. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101407 · Cited by 64
Molecular predictors of response to pembrolizumab in thymic carcinoma
He, Y., Ramesh, A., Gusev, Y., Bhuvaneshwar, K., & Giaccone, G. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100392 · Cited by 67
BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
Huang, S., Pan, C., Lin, Y., Chen, M., Chen, Y., Jan, C., Wu, C., Lin, F., Wang, S. Y., Lin, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202206856 · Cited by 62
Li, F., Yang, Z., Savage, T. M., Vincent, R. L., Santos, K. D. L., Ahn, A., Rouanne, M., Mariuzza, D. L., Danino, T., & Arpaia, N. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn9879 · Cited by 64
“Growing evidence indicates that NK cells can acquire PD-1 expression, such that binding of NK-expressed PD-1 to PD-L1 on cancer cells can also lead to NK cell in-activation ( 43 ).”
BackgroundGenome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ
Zhuang, X., Veltri, D., & Long, E. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02879 · Cited by 65
The Role of NK Cells and Innate Lymphoid Cells in Brain Cancer
Sedgwick, A. J., Ghazanfari, N., Constantinescu, P., Mantamadiotis, T., & Barrow, A. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01549 · Cited by 68
“NK cells respond to “stressed” cells that downregulate MHC class I (MHCI) to evade CTL recognition and are therefore critical for anti-tumor immunity whenever CTL are compromised (3).”
BackgroundNatural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
Poggi, A. D., & Zocchi, M. R. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.016 · Cited by 65
“24 March 2022 PDL1-expressing tumor cells reduces anti-tumor cytotoxicity, allowing tumor growth.(16) The blockade of PD1/PDL1 interaction leads to a rescue of NK cell activity (direct effect), indispensable for the control of neoplasia development, as treatment after depletion of NK cells was ineffective.”
BackgroundTeng, C., Wang, T., Wu, T., Lin, J., Shih, F., Shyu, W., & Jeng, L. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922034 · Cited by 60
The Role of NK Cells in EBV Infection and EBV-Associated NPC
Png, Y. T., Yang, A. Z. Y., Lee, M. Y., Chua, M. J. M., & Lim, C. M. (2021) · Viruses · doi:10.3390/v13020300 · Cited by 60
Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors
Ghaedrahmati, F., Esmaeil, N., & Abbaspour, M. (2022) · 癌症:英文版 · doi:10.1002/cac2.12394 · Cited by 62
“In mice, tumor-infiltrating NK cells express PD-1, and PD1 blocking in NK cells promoted an anti-tumor immune response [132].”
BackgroundsynNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
Lupo, K. B., Yao, X., Borde, S., Wang, J., Torregrosa‐Allen, S. E., Elzey, B. D., Utturkar, S. M., Lanman, N. A., McIntosh, M., & Matosevic, S. (2024) · Nature Communications · doi:10.1038/s41467-024-46343-3 · Cited by 61
“…have included a shift in the balance of surface receptors toward inhibition via upregulation of receptors such as NKG2A 4 and PD-1/PD-L1 5,6 , soluble factors — including metabolites, oncometabolites and immunosuppressive cytokines — also play contributing roles by redirecting the…”
Jun, E., Song, A. Y., Choi, J., Lee, H. H., Kim, M., Ko, D., Kang, H. J., Kim, S. W., Bryceson, Y. T., Kim, S. C., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01354 · Cited by 62
“Although further study is required, these data suggest that NK cells upregulate activation and maturation markers but are rendered more responsive to immune checkpoint pathways during PC progression, corroborating a recent study of the characterization of PD-1+ NK cells co-expressing CD69 in mouse tumor models (47).”
ResultNK Cells in the Treatment of Hematological Malignancies
González, A. P., Villa-Álvarez, M., Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., & Gonzalez, S. R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101557 · Cited by 60
Aso, M., Toi, Y., Sugisaka, J., Aiba, T., Kawana, S., Saito, R., Ogasawara, T., Tsurumi, K., Ono, K., Shimizu, H., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0550 · Cited by 58
“In addition, activated NK cells express PD-1, while PD-1 engagement by PD-L1+ tumor cells potently suppresses NK cell–mediated tumor immunity [37].”
BackgroundTargeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
Alfarra, H., Weir, J. A., Grieve, S., & Reiman, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.575609 · Cited by 62
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi, H., Chrobok, M., Meinke, S., Gran, C., Marquardt, N., Afram, G., Sütlü, T., Gilljam, M., Stellan, B., Wagner, A. K., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100508 · Cited by 62
Khouzam, R. A., Janji, B., Thiery, J., Zaarour, R. F., Chamseddine, A. N., Mayr, H., Savagner, P., Kiéda, C., Gad, S., Buart, S., et al. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.008 · Cited by 58
In situ genetic engineering of tumors for long-lasting and systemic immunotherapy
Tzeng, S. Y., Patel, K. K., Wilson, D. R., Meyer, R. A., Rhodes, K. R., & Green, J. J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916039117 · Cited by 57
“IL-12 is also known to promote NK cell activity (18, 20), which is particularly important in the case of tumor cells that downregulate MHC I expression to avoid immune surveillance.”
BackgroundMetabolism of Innate Immune Cells in Cancer
Talty, R., & Olino, K. L. (2021) · Cancers · doi:10.3390/cancers13040904 · Cited by 60
Targeting natural killer cells to enhance vaccine responses
Cox, A., Cevik, H., Feldman, H. A., Canaday, L. M., Lakes, N., & Waggoner, S. N. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.06.004 · Cited by 56
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
Laba, S., Mallett, G., & Amarnath, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.022 · Cited by 57
Cancer Immunoediting by Innate Lymphoid Cells
Wagner, M., & Koyasu, S. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.03.004 · Cited by 54
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.